文献速递神经肿瘤脑血管病外科

脑肿瘤开颅患者静脉血栓栓塞预防策略的安全性与成本效益的系统综述

Systematic Review of Safety and Cost-Effectiveness of Venous Thromboembolism Prophylaxis Strategies in Patients Undergoing Craniotomy for Brain Tumor.
PubMed 文献 · Neurosurgery · 2018-01-01

该系统综述结合成本效益分析,评估脑肿瘤开颅患者静脉血栓栓塞(VTE)预防策略。共纳入34项研究,机械预防(MP)联合普通肝素(MP+UFH)的VTE概率为1.49%(95%CI 0.42-3.72),MP+LMWH为2.72%(95%CI 1.23-5.15),MP为2.59%(95%CI 1.31-4.58),差异无统计学意义。成本效益分析显示MP+UFH每质量调整生命年成本最低(284.14美元),作者认为在低出血风险患者中MP+UFH可能是最安全且最具成本效益的措施。

要点

  • MP+UFH的VTE概率为1.49%(95%CI 0.42-3.72),MP+LMWH为2.72%(95%CI 1.23-5.15),MP为2.59%(95%CI 1.31-4.58),差异无统计学意义。
  • 颅内出血风险MP为0.26%(95%CI 0.01-1.34),MP+UFH为0.74%(95%CI 0.09-2.61),MP+LMWH为2.72%(95%CI 1.23-5.15),差异无统计学意义。
  • 成本效益分析显示每质量调整生命年成本MP+UFH为284.14美元,MP为338.39美元,MP+LMWH为722.87美元。

核心结论

  • 作者认为,尽管MP+LMWH常被视为降低VTE风险的最佳预防措施,但本模型提示MP+UFH是平衡低出血风险脑肿瘤患者VTE与出血风险中最安全且最具成本效益的措施。
  • 作者认为MP+LMWH可能对VTE风险较高的患者更有效。

研究设计与样本

  • 系统综述结合成本效益分析,文献检索脑肿瘤患者VTE预防研究,纳入报告手术类型、VTE预防选择及结局的文章。
  • 共纳入34项研究(8项评估LMWH,12项评估MP,7项评估UFH单用或联用;4项研究术前使用LMWH和UFH),其中15项研究进入最终成本效益分析。
  • 成本效益分析在开颅术后30天进行,比较MP、MP+LMWH和MP+UFH预防症状性VTE,所有成本以2016年美元报告。

主要发现

  • VTE总体概率:MP+UFH为1.49%(95%CI 0.42-3.72),MP+LMWH为2.72%(95%CI 1.23-5.15),MP为2.59%(95%CI 1.31-4.58),差异无统计学意义。
  • 与单用MP相比,MP+UFH的需治疗人数为91,MP+LMWH为769。
  • 颅内出血风险:MP为0.26%(95%CI 0.01-1.34),MP+UFH为0.74%(95%CI 0.09-2.61),MP+LMWH为2.72%(95%CI 1.23-5.15),差异无统计学意义。
  • 与MP相比,MP+UFH的需伤害人数为208,MP+LMWH为41。
  • 治疗估计成本:MP为127.47美元,MP+UFH为142.20美元,MP+LMWH为169.40美元;每质量调整生命年成本:MP+UFH为284.14美元,MP为338.39美元,MP+LMWH为722.87美元。

临床怎么用

  • 作者认为,对于出血风险较低的脑肿瘤患者,MP+UFH可能是平衡VTE与出血风险中最安全且最具成本效益的措施。
  • 作者认为,MP+LMWH可能对VTE风险较高的患者更有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have evaluated various strategies to prevent venous thromboembolism (VTE) in neuro-oncology patients, without consensus. OBJECTIVE: To perform a systematic review with cost-effectiveness analysis (CEA) of various prophylaxis strategies in tumor patients undergoing craniotomy to determine the safest and most cost-effective prophylaxis regimen. METHODS: A literature search was conducted for VTE prophylaxis in brain tumor patients. Articles reporting the type of surgery, choice of VTE prophylaxis, and outcomes were included. Safety of prophylaxis strategies was determined by measuring rates of VTE and intracranial hemorrhage. Cost estimates were collected based on institutional data and existing literature. CEA was performed at 30 d after craniotomy, comparing the following strategies: mechanical prophylaxis (MP), low molecular weight heparin with MP (MP+LMWH), and unfractionated heparin with MP (MP+UFH) to prevent symptomatic VTE. All costs were reported in 2016 US dollars. RESULTS: A total of 34 studies were reviewed (8 studies evaluated LMWH, 12 for MP, and 7 for UFH individually or in combination; 4 studies used LMWH and UFH preoperatively). Overall probability of VTE was 1.49% (95% confidence interval (CI) 0.42-3.72) for MP+UFH, 2.72% [95% CI 1.23-5.15] for MP+LMWH, and 2.59% (95% CI 1.31-4.58) for MP, which were not statistically significant. Compared to a control of MP alone, the number needed to treat for MP+UFH is 91 and 769 for MP+LMWH. The risk of intracranial hemorrhage was 0.26% (95% CI 0.01-1.34) for MP, 0.74% (95% CI 0.09-2.61) for MP+UFH, and 2.72% (95% CI 1.23-5.15) for MP+LMWH, which were also not statistically significant. Compared to MP, the number needed to harm for MP+UFH was 208 and for MP+LMWH was 41. Fifteen studies were included in the final CEA. The estimated cost of treatment was $127.47 for MP, $142.20 for MP+UFH, and $169.40 for MP+LMWH. The average cost per quality-adjusted life-year for different strategies was $284.14 for MP+UFH, $338.39 for MP, and $722.87 for MP+LMWH. CONCLUSION: Although MP+LMWH is frequently considered the optimal prophylaxis for VTE risk reduction, our model suggests that MP+UFH is the safest and most cost-effective measure to balance VTE and hemorrhage risks in brain tumor patients at lower risk of hemorrhage. MP+LMWH may be more effective for patients at higher risk of VTE.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Algattas H, Damania D, DeAndrea-Lazarus I, et al. Systematic Review of Safety and Cost-Effectiveness of Venous Thromboembolism Prophylaxis Strategies in Patients Undergoing Craniotomy for Brain Tumor. Neurosurgery. 2018. PMID: 28402497. doi:10.1093/neuros/nyx156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。